Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-β-D-arabinofuranosylcytosine, a new anticancer drug

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 3, 1997, Pages 1572-1580

  Koller Lucae, Sibylle K M ^a   Schott, Herbert ^b   Schwendener, Reto A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE DERIVATIVE; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; N4 OCTADECYL 1 BETA D ARABINOFURANOSYLCYTOSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG UPTAKE; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CYTARABINE; DRUG CARRIERS; ERYTHROCYTES; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, INBRED ICR; PROTEIN BINDING;

EID: 0030924555     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. ALLEN, T. M.: Stealth-liposomes: Avoiding reticuloendothelial uptake. In Liposomes in the Therapy of Infectious Diseases and Cancer, ed. by G. Lopez-Berenstein and I. J. Fidler, pp. 405-415. Alan R. Liss, New York, 1989.
2. ALLEN, T. M., MEHRA, T., HANSEN, C. AND CHIN, Y. C.: Stealth liposomes: an improved sustained release system for 1-β-D-arabinofuranosylcytosine. Cancer Res. 52: 2431-2439. 1992.
3. 4-acyl-1-β-D-arabinofuranosylcytosine. Cancer Res. 36: 2726-2732, 1976.
4. BORSA, J., WHITMORE, G. R., VALERIOTE, F. A., COLLINS, D. AND BRUCE, W. R.: Studies on the persistence of methotrexate, cytosine arabinoside, and leucovorin in the serum of mice. J. Natl. Cancer Inst. 42: 235-242, 1969.
5. CHAPMAN, M. J., GOLDSTEIN, S., LAGRANGE, D. AND LAPLAUD, P. M.: A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 22: 339-358, 1981.
6. DE SMIDT, P. C. AND VAN BERKEL, T. J. C.: Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res. 50: 7476-7482, 1990.
7. DE SMIDT, P. C., VERSLUIS, A. J. AND VAN BERKEL, T. J.: Properties of incorporation, redistribution, and integrity of porphyrin-low-density lipoprotein complexes. Biochemistry 32: 2916-2922, 1993.
8. DERENDORF, H. AND GARRETT, E. R.: High-performance liquid chromatographic assay of methadone, phencyclidine, and metabolites by postcolumn ion-pair extraction and on-line fluorescent detection of the counterion with applications. J. Pharm. Sci. 72: 630-635, 1983.
9. FIRESTONE, R. A.: Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug. Chem. 5: 105-113, 1994.
10. GAHRTON, G.: Treatment of acute leukemia: Advances in chemotherapy, immunotherapy and bone marrow transplantation. Adv. Cancer Res. 40: 255-329, 1983.
11. GERKE, A., WESTENSEN, K. AND KOCH, M. H. J.: Physicochemical characterization of protein-free low density lipoprotein models and influence of drug loading. Pharm. Res. 13: 44-51, 1996.
12. GINEVRA, F., BIFFANTI, S., PAGNAN, A., BIOLO, R., REDDI, E. AND JORI, G.: Delivery of the tumour photosensitizer zinc(II)-phthalocyanine to serum proteins by different liposomes: Studies in vitro and in vivo. Cancer Lett. 49: 59-65, 1990.
13. GREENBLATT, D. J. AND KOCH-WESER, J.: Clinical pharmacokinetics (first of two parts). N. Engl. J. Med. 2: 702-705, 1975.
14. HO, D. H. AND FREI, E., III: Clinical pharmacology of 1-β-D-arabinofuranosyl cytosine. Clin. Pharmacol. Ther. 12: 944-954, 1971.
15. HOPE, M. J., BALLY, M. B., WEBB, G. AND CULLIS, P. R.: Production of large unilamellar vesicles by a rapid procedure, characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 812: 55-65, 1985.
16. 4-1-β-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J. Pharm. Pharmacol. 47: 282-288, 1995a.
17. 4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br. J. Cancer 71: 957-962, 1995b.
18. 4-hexadecyl-1-β-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Cancer Chemother. Pharmacol. 36: 483-492, 1995c.
19. 4-hexadecyl-1-β-D-arabinofuranosylcytosine. Br. J. Cancer 72: 1067-1073, 1995d.
20. KAMP, F., HAMILTON, J. A. AND WESTERHOFF, H. V.: Movement of fatty acids, fatty acid analogues, and bile acids across phospholipid bilayers. Biochemistry 32: 11074-11086, 1993.
21. 4-substituted 2,2′-anhydronucleosides. J. Med. Chem. 17: 1076-1078, 1974.
22. 4-behenoyl-β-D-arabinofuranosylcytosine. Recent Results. Cancer Res. 70: 147-151, 1980.
23. KEATING, M. J., MCCREDIE, K. B., BODEY, G. P., SMITH, T. L., GEHAN, E. AND FREIREICH, E. J.: Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 248: 2481-2486, 1982.
24. KLEINFELD, A. M. AND STORCH, J.: Transfer of long-chain fluorescent fatty acids between small and large unilamellar vesicles. Biochemistry 32: 2053-2061, 1993.
25. NISHIKAWA, M., KAMIJO, A., FUJITA, T., TAKAKURA, Y., SEZAKI, H. AND HASHIDA, M.: Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxytnethyl-dextran, and its application to drug targeting. Pharm. Res. 10: 1253-1261, 1993.
26. NOBLE, R. P.: Electrophoretic separation of plasma lipoproteins in agarose gel. J. Lipid Res. 9: 693-700, 1968.
27. PLUNKETT, W. AND GANDHI, V.: Cellular pharmacodynamics of anticancer drugs. Semin. Oncol. 20: 50-63, 1993.
28. REDDI, E., ZHOU, C., BIOLO, R., MENEGALDO, E. AND JOBI, G.: Liposome-or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency. Br. J. Cancer 61: 407-411, 1990.
29. REDGRAVE, T. G., ROBERTS, D. C. K. AND WEST, C. E.: Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem. 65: 42-49, 1975.
30. RENSEN, P. C., LOVE, W. G. AND TAYLOR, P. W.: In vitro interaction of zinc(II)-phthalocyanine-containing liposomes and plasma lipoproteins. J. Photochem. Photobiol. B 26: 29-35, 1994.
31. 4-octadecyl-1-β-D-arabinofuranosylcytosine in plasma and erythrocytes. J. Chromatogr. B 673: 259-266, 1995.
32. RICHIERI, G. V., ANEL, A. AND KLEINFELD, A. M.: Interactions of long-chain fatty acids and albumin: Determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry 32: 7574-7580, 1993.
33. 4-acyl and 2,2′-anhydro-3′-O-acyl derivatives as potential prodrugs. J. Med. Chem. 25: 171-178, 1982.
34. RUBAS, W., SUPERSAXO, A., WEDER, H. G., HARTMANN, H. R., HENGARTNER, H., SCHOTT, H. AND SCHWENDENER, R.: Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int. J. Cancer 37: 149-154, 1986.
35. SCHMIDT-ERFURTH, U., DIDDENS, H., BIRNGRUBER, R. AND HASAN, T.: Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br. J. Cancer 75: 54-61, 1997.
36. 4-alkyl derivatives of 1-β-D-arabinofuranosyl-cytosine. J. Cancer Res. Clin. Oncol. 122: 102-108, 1996.
37. 4-octadecyl-ara-C, NOAC. Drugs Future 20: 11-15, 1995a.
38. 4-octadecyl-1-β-D-arabinofuranosyleytosine in liposomal preparations. J. Liposome Res. 5: 27-47, 1995b.
39. 4-hexadecyl-1-β-D-arabinofuranosylcytosine. Int. J. Cancer 51: 466-469, 1992.
40. SCHWENDENER, R. A. AND SCHOTT, H.: Lipophilic 1-β-D-arabinofuranosylcytosine (Ara-C) derivatives in liposomal formulations for the oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J. Cancer Res. Clin. Oncol. 122: 723-726, 1996.
41. 4-stearoyl-1-β-D-arabinofuranosylcytosine as new antitumor agent. In Current Chemotherapy and Infections Disease, ed. by J. D. Grassi, pp. 1591-1593, The American Society of Microbiology, Washington, DC, 1980.
42. 4-behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia. Cancer Res. 43: 3412-3416, 1983.
43. VAAGE, J., BARBERA GUILLEM, E., ABRA, R., HUANG, A. AND WORKING, P.: Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73: 1478-1484, 1994.
44. VITOLS, S., ANGELIN, B., ERICSSON, S., GAHRTON, G., JULIUSSON, G., MASQUELIER, M., PAUL, C., PETERSON, C., RUDLING, M., SODERBERG REID, K. AND TIDEFELT, U.: Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 87: 2598-2602, 1990.
45. 4-substituted derivatives of 1-β-D-arabinofuranosyleytosine and -5-5-fluorocytosine. J. Med. Chem. 11: 144-148, 1968.